Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429

References

• Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–1011.
   PubMed Web of Science ®Google Scholar
• Kudchadkar RR, Lowe MC, Khan MK, et al. Metastatic melanoma. CA Cancer J Clin. 2020;70(2):78–85.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Pavri SN, Clune J, Ariyan S, et al. Malignant melanoma: beyond the basics. Plast Reconstr Surg. 2016;138(2):330e–40e.
   PubMed Web of Science ®Google Scholar
• Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol. 2014;36(5):363–379.
   PubMed Web of Science ®Google Scholar
• Shang Q, Li Y, Wang H, et al. Altered expression profile of circular RNAs in conjunctival melanoma. Epigenomics. 2019;11(7):787–804.
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Lu NH, et al. Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. Mol Cancer. 2020;19(1):84.
   PubMed Web of Science ®Google Scholar
• Luan W, Shi Y, Zhou Z, et al. circRNA_0084043 promote malignant melanoma progression via miR-153-3p/Snail axis. Biochem Biophys Res Commun. 2018;502(1):22–29.
   PubMed Web of Science ®Google Scholar
• Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268–273.
   PubMed Web of Science ®Google Scholar
• McHugh JB, Fullen DR, Ma L, et al. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007;34(8):597–600.
   PubMed Web of Science ®Google Scholar
• Fan T, Jiang S, Chung N, et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 2011;9(4):418–429.
   PubMed Web of Science ®Google Scholar
• Tiffen JC, Gunatilake D, Gallagher SJ, et al. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget. 2015;6(29):27023–27036.
   PubMedGoogle Scholar
• Liu D, Xia P, Diao D, et al. MiRNA-429 suppresses the growth of gastric cancer cells in vitro. J Biomed Res. 2012;26:389–393.
   PubMedGoogle Scholar
• Su Z, Jiang G, Chen J, et al. MicroRNA-429 inhibits cancer cell proliferation and migration by targeting AKT1 in renal cell carcinoma. Mol Clin Oncol. 2020;12:75–80.
   PubMed Web of Science ®Google Scholar
• Peng G, Liao Y, Shen C. miRNA-429 inhibits astrocytoma proliferation and invasion by targeting BMI1. Pathol Oncol Res. 2017;23(2):369–376.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Yang X, Jiang J, Zhang C, et al. Baicalein restrains proliferation, migration, and invasion of human malignant melanoma cells by down-regulating colon cancer associated transcript-1. Braz J Med Biol Res = Rev Bras Pesqui Med Biol. 2019;52(12):e8934.
   PubMed Web of Science ®Google Scholar
• Chen XE, Chen P, Chen S, et al. Long non-coding RNA FENDRR inhibits migration and invasion of cutaneous malignant melanoma cells. Biosci Rep. 2020;40(3):BSR20191194.
   PubMedGoogle Scholar
• Chen G, Xie Y. miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells. Onco Targets Ther. 2018;11:1909–1920.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen J, Wa Q, et al. Knockdown of circ_0084043 suppresses the development of human melanoma cells through miR-429/tribbles homolog 2 axis and Wnt/β-catenin pathway. Life Sci. 2020;243:117323.
   PubMed Web of Science ®Google Scholar
• Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107–129.
   PubMedGoogle Scholar
• Testori AAE, Blankenstein SA, van Akkooi ACJ. Primary melanoma: from history to actual debates. Curr Oncol Rep. 2019;21(12):112.
   PubMed Web of Science ®Google Scholar
• Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345–358.
   PubMed Web of Science ®Google Scholar
• Pampena R, Lai M, Piana S, et al. Nevus-associated melanoma: facts and controversies. G Ital Dermatol Venereol. 2020;155(1):65–75.
   PubMed Web of Science ®Google Scholar
• Joyce D, Skitzki JJ. Surgical management of primary cutaneous melanoma. Surg Clin North Am. 2020;100(1):61–70.
   PubMed Web of Science ®Google Scholar
• Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol. 2019;20(1):7.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Veno MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–565.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50–60.
   PubMed Web of Science ®Google Scholar
• Shang S, Hua F, Hu ZW. The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8(20):33972–33989.
   PubMedGoogle Scholar
• Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164:257–264.
   PubMed Web of Science ®Google Scholar
• Huang D, Wang F, Wu W, et al. MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma. Cancer Biomark. 2019;26:63–68.
   PubMed Web of Science ®Google Scholar
• Sheng H, Guo YH, Cao DS, et al. MiR-429-5p attenuates the migration and invasion of malignant melanoma by targeting LIMK1. Eur Rev Med Pharmacol Sci. 2020;24:2625–2631.
   PubMed Web of Science ®Google Scholar